
Quarterly ResultAug 10, 2026, 04:16 PM
Alamar Biosciences Q2 Revenue Up 82% to $29.4M; Guides FY26 $116-120M
AI Summary
Alamar Biosciences reported strong second quarter 2026 financial results, with total revenue increasing 82% year-over-year to $29.4 million, driven by significant growth in consumable revenue. The company also launched new products, including a multiplexed blood-based immunoassay for eMTBR-tau and the NULISAseq™ Immune 340 Panel, and expanded a strategic partnership. Despite increased operating expenses leading to a higher net loss of $13.2 million, Alamar Biosciences provided optimistic full-year 2026 revenue guidance of $116 million to $120 million.
Key Highlights
- Q2 2026 total revenue increased 82% to $29.4 million.
- Consumable revenue grew 147% to $15.5 million in Q2 2026.
- Instrument revenue grew 35% to $7.8 million in Q2 2026.
- Gross margin improved to 60% in Q2 2026 from 53% in Q2 2025.
- Net loss was $13.2 million in Q2 2026, up from $7.0 million in Q2 2025.
- Cash, cash equivalents, and short-term investments totaled $256.3 million as of June 30, 2026.
- Launched commercial multiplexed blood-based immunoassay for eMTBR-tau.
- Providing full-year 2026 revenue guidance of $116 million to $120 million.
Price Impact
More from ALMR